Lexaria Bioscience Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.9%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$4.05next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Fiscal Year 2026 Annual Report (Form 10-K) | 27 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Reduction in Total Adverse Events (DHT-semaglutide vs. Rybelsus) Annually47.9Target: Maintain >45% reduction in chronic dosing
Reduction in Gastrointestinal Adverse Events (DHT-semaglutide vs. Rybelsus) Annually55.0Target: Maintain >50% reduction in chronic dosing
Reduction in Adverse Events (DHT-liraglutide vs. Saxenda) Annually22.7Target: Establish comparable safety profile in oral format
Watch Items
- Human Pilot Study #7 (GLP-1-H26-7) Clinical ReadoutTrigger: Completion of 5-week parallel group evaluation comparing SNAC-inclusive DHT-sema tablet/capsule formulations to Wegovy® tabletsAction: Analyze pharmacokinetic (PK) steady-state concentrations and safety/tolerability profiles to support commercial licensing discussions
- Nasdaq Minimum Bid Price ComplianceTrigger: Failure to maintain $1.00 minimum bid price (deficiency notice received Feb 4, 2026)Action: Monitor share price performance and evaluate corporate actions, such as a reverse stock split, to preserve Nasdaq listing
- Material Transfer Agreement (MTA) Partner EngagementTrigger: Expiration of extended MTA with undisclosed global pharmaceutical partner on December 31, 2026Action: Share human and animal study data to transition the pre-clinical/clinical evaluation into a formal commercial licensing agreement
Research as of 20 Jun 2026